<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024150</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190394</org_study_id>
    <secondary_id>2019-A00926-51</secondary_id>
    <nct_id>NCT04024150</nct_id>
  </id_info>
  <brief_title>Pregnancy, Anti-integrase and Lymphocyte Repertoire of the Newborn</brief_title>
  <acronym>RAGIIF</acronym>
  <official_title>Impact of in Utero Exposure to Anti-integrase Antiretrovirals on the Newborn Immune System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate at birth, the diversity of the T repertoire of
      newborns exposed in utero to anti-integrases in comparison with a control group of children
      exposed to other antiretroviral drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiretroviral treatment during pregnancy is remarkably effective in preventing the
      transmission of mother-to-child viruses. Molecules of the class of anti-integrases are still
      little used during pregnancy, but their prescription is increasing given their intrinsic
      effectiveness and their overall tolerance profile.

      The integrase of HIV-1, responsible for the integration of viral DNA in cellular DNA, has a
      functional similarity with human RAG1 / 2 proteins, responsible for V (D) J recombination.
      RAG1 / 2 proteins alteration is associated in human clinic with immune disturbances of varied
      severity.

      The objective of the study is to evaluate at birth, the diversity of the T repertoire of
      newborns exposed in utero to anti-integrases in comparison with a control group of children
      exposed to other antiretroviral drugs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Newborn immunity</measure>
    <time_frame>18 months</time_frame>
    <description>T cells immune repertoire integrity</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anti-integrases</condition>
  <arm_group>
    <arm_group_label>Newborns exposed</arm_group_label>
    <description>Newborns exposed in-utero to raltegravir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newborns controls</arm_group_label>
    <description>Newborns exposed to antiretroviral therapy without anti-integrase</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Single blood sample of 2 ml at birth on the occasion of blood sampling routine checkup</description>
    <arm_group_label>Newborns controls</arm_group_label>
    <arm_group_label>Newborns exposed</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Newborns exposed in utero to an antiretroviral therapy and born in the maternities of Paris
        AP-HP hospitals: Necker, Pitié-Salpétrière, Bichat, Louis Mourier and Cochin (Port-Royal).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No parental opposition after information. &quot;Exposed&quot; group :

          -  Newborn at term exposed to raltegravir (RTG) before 8 weeks of gestation and until the
             end of pregnancy. Children exposed to elvitegravir (ETG), dolutegravir (DTG) or
             bictegravir (BTG) may be included but will be analyzed separately.

        &quot;Control&quot; group :

        - Term neonate exposed to antiretroviral therapy without anti-integrase.

        Exclusion Criteria:

          -  Prematurity less than 36 weeks of gestation.

          -  Organ dysfunction.

          -  Acute or chronic fetal distress, need for hospitalization in neonatology, malformation
             syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Blanche, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Pierre de Villartay</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphane Blanche, MD-PhD</last_name>
    <phone>+ 33 1 44 49 48 24</phone>
    <email>stephane.blanche@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Morel</last_name>
    <phone>+33 1 71 19 63 46</phone>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP, Hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent MANDELBROT, MD</last_name>
      <phone>+33 1 47 60 63 37</phone>
      <email>aurent.mandelbrot@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital de la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland TUBIANA, MD</last_name>
      <phone>+33 1 42 16 01 18</phone>
      <email>roland.tubiana@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle PANNIER METZGER, MD</last_name>
      <phone>+33 1 58 41 38 18</phone>
      <email>emmanuelle.pannier@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Blanche, MD-PhD</last_name>
      <phone>+ 33 1 44 49 48 24</phone>
      <email>stephane.blanche@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP, Hôpital Bichat-Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jade GHOSN, MD</last_name>
      <phone>+33 1 40 25 78 03</phone>
      <email>jade.ghosn@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-integrases treatment</keyword>
  <keyword>Antiretroviral treatment</keyword>
  <keyword>Pregnancy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

